Combination peptide immunotherapy suppresses antibody and helper T cell responses to the RhD protein in HLA-transgenic mice

Lindsay S Hall, Andrew M Hall, Wendy Pickford, Mark A Vickers, Stanislaw J Urbaniak, Robert N Barker

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The offspring from pregnancies of women who have developed anti-D blood group antibodies are at risk of hemolytic disease of the newborn. We have previously mapped four peptides containing immunodominant T-helper cell epitopes from the RhD protein and the purpose of the work was to develop these into a product for suppression of established anti-D responses. A panel of each of the four immunodominant RhD peptides was synthesized with modifications to improve manufacturability and solubility, and screened for retention of recognition by human T-helper cells. A selected version of each sequence was combined in a mixture (RhDPmix), which was tested for suppressive ability in a humanized murine model of established immune responses to RhD protein. After HLA-DR15 transgenic mice had been immunized with RhD protein, a single dose of RhDPmix, given either intranasally (p=0.008, Mann-Whitney rank sum test) or subcutaneously (p=0.043), rapidly and significantly suppressed the ongoing antibody response. This was accompanied by reduced T-helper cell responsiveness, although this change was less marked for subcutaneous RhDPmix delivery, and by the recruitment of cells with a regulatory T-cell phenotype. The results support human trials of RhDPmix peptide immunotherapy in women with established antibody responses to the RhD blood group.
Original languageEnglish
Pages (from-to)588-596
Number of pages9
JournalHaematologica
Volume99
Issue number3
Early online date17 Jan 2014
DOIs
Publication statusPublished - 1 Mar 2014

Fingerprint

Helper-Inducer T-Lymphocytes
Immunotherapy
Transgenic Mice
Blood Group Antigens
Peptides
Antibody Formation
Antibodies
Fetal Erythroblastosis
Immunodominant Epitopes
Proteins
T-Lymphocyte Epitopes
Regulatory T-Lymphocytes
Nonparametric Statistics
Solubility
Phenotype
Pregnancy
RHO(D) antibody

Keywords

  • HLA-DR transgenic mice
  • hemolytic disease of the newborn
  • peptide therapy
  • regulatory T cell
  • RhD

Cite this

Combination peptide immunotherapy suppresses antibody and helper T cell responses to the RhD protein in HLA-transgenic mice. / Hall, Lindsay S; Hall, Andrew M; Pickford, Wendy; Vickers, Mark A; Urbaniak, Stanislaw J; Barker, Robert N.

In: Haematologica, Vol. 99, No. 3, 01.03.2014, p. 588-596.

Research output: Contribution to journalArticle

Hall, Lindsay S ; Hall, Andrew M ; Pickford, Wendy ; Vickers, Mark A ; Urbaniak, Stanislaw J ; Barker, Robert N. / Combination peptide immunotherapy suppresses antibody and helper T cell responses to the RhD protein in HLA-transgenic mice. In: Haematologica. 2014 ; Vol. 99, No. 3. pp. 588-596.
@article{953ba4889fac464cb216931313744aef,
title = "Combination peptide immunotherapy suppresses antibody and helper T cell responses to the RhD protein in HLA-transgenic mice",
abstract = "The offspring from pregnancies of women who have developed anti-D blood group antibodies are at risk of hemolytic disease of the newborn. We have previously mapped four peptides containing immunodominant T-helper cell epitopes from the RhD protein and the purpose of the work was to develop these into a product for suppression of established anti-D responses. A panel of each of the four immunodominant RhD peptides was synthesized with modifications to improve manufacturability and solubility, and screened for retention of recognition by human T-helper cells. A selected version of each sequence was combined in a mixture (RhDPmix), which was tested for suppressive ability in a humanized murine model of established immune responses to RhD protein. After HLA-DR15 transgenic mice had been immunized with RhD protein, a single dose of RhDPmix, given either intranasally (p=0.008, Mann-Whitney rank sum test) or subcutaneously (p=0.043), rapidly and significantly suppressed the ongoing antibody response. This was accompanied by reduced T-helper cell responsiveness, although this change was less marked for subcutaneous RhDPmix delivery, and by the recruitment of cells with a regulatory T-cell phenotype. The results support human trials of RhDPmix peptide immunotherapy in women with established antibody responses to the RhD blood group.",
keywords = "HLA-DR transgenic mice, hemolytic disease of the newborn, peptide therapy, regulatory T cell, RhD",
author = "Hall, {Lindsay S} and Hall, {Andrew M} and Wendy Pickford and Vickers, {Mark A} and Urbaniak, {Stanislaw J} and Barker, {Robert N}",
year = "2014",
month = "3",
day = "1",
doi = "10.3324/haematol.2012.082081",
language = "English",
volume = "99",
pages = "588--596",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "3",

}

TY - JOUR

T1 - Combination peptide immunotherapy suppresses antibody and helper T cell responses to the RhD protein in HLA-transgenic mice

AU - Hall, Lindsay S

AU - Hall, Andrew M

AU - Pickford, Wendy

AU - Vickers, Mark A

AU - Urbaniak, Stanislaw J

AU - Barker, Robert N

PY - 2014/3/1

Y1 - 2014/3/1

N2 - The offspring from pregnancies of women who have developed anti-D blood group antibodies are at risk of hemolytic disease of the newborn. We have previously mapped four peptides containing immunodominant T-helper cell epitopes from the RhD protein and the purpose of the work was to develop these into a product for suppression of established anti-D responses. A panel of each of the four immunodominant RhD peptides was synthesized with modifications to improve manufacturability and solubility, and screened for retention of recognition by human T-helper cells. A selected version of each sequence was combined in a mixture (RhDPmix), which was tested for suppressive ability in a humanized murine model of established immune responses to RhD protein. After HLA-DR15 transgenic mice had been immunized with RhD protein, a single dose of RhDPmix, given either intranasally (p=0.008, Mann-Whitney rank sum test) or subcutaneously (p=0.043), rapidly and significantly suppressed the ongoing antibody response. This was accompanied by reduced T-helper cell responsiveness, although this change was less marked for subcutaneous RhDPmix delivery, and by the recruitment of cells with a regulatory T-cell phenotype. The results support human trials of RhDPmix peptide immunotherapy in women with established antibody responses to the RhD blood group.

AB - The offspring from pregnancies of women who have developed anti-D blood group antibodies are at risk of hemolytic disease of the newborn. We have previously mapped four peptides containing immunodominant T-helper cell epitopes from the RhD protein and the purpose of the work was to develop these into a product for suppression of established anti-D responses. A panel of each of the four immunodominant RhD peptides was synthesized with modifications to improve manufacturability and solubility, and screened for retention of recognition by human T-helper cells. A selected version of each sequence was combined in a mixture (RhDPmix), which was tested for suppressive ability in a humanized murine model of established immune responses to RhD protein. After HLA-DR15 transgenic mice had been immunized with RhD protein, a single dose of RhDPmix, given either intranasally (p=0.008, Mann-Whitney rank sum test) or subcutaneously (p=0.043), rapidly and significantly suppressed the ongoing antibody response. This was accompanied by reduced T-helper cell responsiveness, although this change was less marked for subcutaneous RhDPmix delivery, and by the recruitment of cells with a regulatory T-cell phenotype. The results support human trials of RhDPmix peptide immunotherapy in women with established antibody responses to the RhD blood group.

KW - HLA-DR transgenic mice

KW - hemolytic disease of the newborn

KW - peptide therapy

KW - regulatory T cell

KW - RhD

U2 - 10.3324/haematol.2012.082081

DO - 10.3324/haematol.2012.082081

M3 - Article

VL - 99

SP - 588

EP - 596

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 3

ER -